
Alector Inc (ALEC) Stock Forecast & Price Target
Alector Inc (ALEC) Analyst Ratings
Bulls say
Alector Inc's innovative approach to neurodegenerative therapies, particularly through its advanced therapeutic candidates like AL137, AL050, and ADP064-ABC, is supported by a differentiated transferrin receptor binding technology that demonstrates significant brain uptake and favorable safety profiles. The company's focus on standardized AD biomarkers, such as pTau and amyloid PET, enhances the likelihood of achieving meaningful clinical outcomes, which could serve as positive catalysts for stock performance. Additionally, the potential for early proof-of-concept data from the ABC programs may unlock substantial shareholder value given the large addressable market within these major indications.
Bears say
Alector Inc's stock outlook has become unfavorable due to the failure of the INFRONT-3 trial of latozinemab to meet its primary endpoint, indicating significant translational biology risks that negatively impact the company's therapeutic promise. Additionally, there are substantial concerns regarding the potential failure of AL101, AL001, and AL002 to gain regulatory approval and achieve the anticipated commercial revenue, driven by limitations in market size and penetration. Furthermore, the company's valuation hinges on a discounted cash flow analysis which reflects added risks from potential negative outcomes in ongoing clinical trials and unforeseen adverse effects from its products.
This aggregate rating is based on analysts' research of Alector Inc and is not a guaranteed prediction by Public.com or investment advice.
Alector Inc (ALEC) Analyst Forecast & Price Prediction
Start investing in Alector Inc (ALEC)
Order type
Buy in
Order amount
Est. shares
0 shares